Fondaparinux overdosage

Fondaparinux
Arixtra® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Fondaparinux
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ahmed Zaghw, M.D. [2]

Overdosage

• There is no known antidote for ARIXTRA. Overdose of ARIXTRA may lead to hemorrhagic complications.
• Discontinue treatment and initiate appropriate therapy if bleeding complications associated with overdosage occur.
• Data obtained in patients undergoing chronic intermittent hemodialysis suggest that clearance of ARIXTRA can increase by 20% during hemodialysis.

References

Adapted from the FDA Package Insert.